Balyasny Asset Management
PYXS icon

Balyasny Asset Management’s Pyxis Oncology PYXS Stock Holding History

Balyasny Asset Management’s Portfolio PYXS Stock Details PYXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.08K Sell
743
-7,484
-91% -$11.3K ﹤0.01% 2805
2025
Q4 		$9.46K Buy
+8,227
New +$29K ﹤0.01% 3026
2024
Q4 		– Sell
-224,957
Closed -$826K – 3169
2024
Q3 		$826K Sell
224,957
-2,337,985
-91% -$8.18M ﹤0.01% 2043
2024
Q2 		$8.48M Sell
2,562,942
-31,382
-1% -$132K 0.01% 957
2024
Q1 		$11.1M Buy
+2,594,324
New +$10.9M 0.02% 876

Other funds holding PYXS

P
Pfizer New York $239M AUM 232.47% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
GGI
GordonMD Global Investments Beverely Hills, California $144M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
HP
HealthInvest Partners Stockholm, Sweden $310M AUM 37.86% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
6CM
683 Capital Management New York $1.92B AUM 85.52% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Balyasny Asset Management's PYXS Position: Q1 2026 in Review

Balyasny Asset Management reduced its Pyxis Oncology (PYXS) stake by 91% in Q1 2026, selling an estimated $11.3K and leaving 743 shares worth $1.08K. The position accounts for ﹤0.01% of the portfolio, ranked #2805.

Balyasny Asset Management first reported a position in PYXS in Q1 2024 and has held it in 5 quarters since. The position peaked at $11.1M in Q1 2024. 78 funds tracked by Wall St. Rank hold PYXS as of Q1 2026.

  • Balyasny Asset Management held 743 shares of Pyxis Oncology worth $1.08K as of Q1 2026.
  • Balyasny Asset Management sold 7,484 Pyxis Oncology shares in Q1 2026, an estimated $11.3K.
  • Pyxis Oncology made up ﹤0.01% of Balyasny Asset Management's portfolio in Q1 2026, its #2805 holding.
  • Balyasny Asset Management first reported a position in Pyxis Oncology in Q1 2024 and has held it in 5 quarters since.
  • Balyasny Asset Management's Pyxis Oncology position peaked at $11.1M in Q1 2024.
  • 78 funds tracked by Wall St. Rank held Pyxis Oncology as of Q1 2026.

Based on Balyasny Asset Management's 13F filing for Q1 2026, filed 15 May 2026.